Clinical Topics & News
News
FDA Okays Subcutaneous Ocrelizumab for MS
The subcutaneous (SC) injection can be administered by a healthcare professional in approximately 10 minutes and is the first and only twice-a-...
Opinion
Despite ongoing challenges, experts are optimistic about the future of MS therapy
To celebrate our 30th year in print, Neurology Reviews invited experts to look back on the trajectories of various neurology subspecialties. In...
Literature Review
Ublituximab bests teriflunomide in head-to-head clinical trials
The results of the ULTIMATE I and II trials may pave the way for ublituximab’s approval as the third high-efficacy anti-CD20 monoclonal antibody...
News
COVID vaccination in DMT-treated MS patients: New data
News
B-cell level may affect COVID booster efficacy in MS
“It’s meaningless to just go by some recommendation covering time since the last treatment.”
News
Childhood abuse may increase risk of MS in women
Women exposed to all three types of abuse – emotional, physical, and sexual – had the highest risk of MS, at 93%.
News
MS fundraising during a pandemic
The National MS Society describes how the pandemic impacted their in-person fundraising events.
News
MS plus depression can increase risk of death, vascular disease
“The effects of depression and MS on all-cause mortality are synergistic.”
Literature Review
MRI is a poor disability predictor in secondary progressive MS
Literature Review
Progressive disability in MS explained?
Complete resolution of brain lesions may help distinguish MS, MOGAD, and AQP4+ NMOSD.